Stock: PYC Therapeutics (PYC)Top Management and Board of DirectorsTop ManagementTop Management [One top executive with tenure > 6 yrs]
Top Management [Three top executives with tenure < 2 yrs]
Board Of DirectorsBoard Of Directors [Three directors with tenure < 5 yrs]
Resignations in the past 3 years
Profiles of Top ManagementRohan HockingsCEO Rohan Hockings holds double degrees in medicine and law. He has worked across both disciplines following an internship at Sir Charles Gairdner Hospital and admission to practice in the Supreme Court of Victoria respectively. He spent four years with McKinsey & Company and a further two years in the Private Equity industry before joining PYC Therapeutics. Rohan brings a deep affinity for conceptual thinking to PYC Therapeutics along with an understanding of the company's technology and its commercialisation path. Paula Cunningham Vice President Paula holds a PhD in Microbiology, a Bachelor of Science in Molecular Genetics with Honors in Microbiology and a Masters in Environmental Science. She is an experienced scientist with excellent analytical, project management and team building skills. Paula has a strong background in molecular genetics, cell biology and immunology, with specific expertise in allergy and cancer research. Her research interests focus on the development of highly efficient delivery methods for gene therapies of disease with specific emphasis on inherited retinal diseases. Prior to working at PYC Therapeutics, Paula was Group Leader of Bioassay Development for Phylogica Limited and a Senior Research Officer for Telethon Kids Institute in Perth, Western Australia. Profiles of Board of DirectorsMichael RosenblattNon-Executive Director Dr. Michael Rosenblatt is a currently a Senior Partner at Flagship Pioneering. Dr. Rosenblatt joined Flagship from Merck, where he served as Executive Vice President and Chief Medical Officer from 2009 to 2016. During an earlier period at Merck, he led drug discovery efforts in ophthalmology, molecular biology, bone biology, virology, cancer research, gastroenterology, lipid metabolism and cardiovascular research. He has held appointments as Dean of Tufts University School of Medicine; Robert H. Ebert Professor of Molecular Medicine and George R. Minot Professor of Medicine, both at Harvard Medical School; President, Harvard Faculty Dean and Senior Vice President for Academic Programs of Beth Israel Deaconess Medical Center; and Director of the Harvard-MIT Division of Health Sciences and Technology. Dr. Rosenblatt has served as a founding scientist, scientific advisory board member or director of more than 12 biopharmaceutical companies. He received his BA summa cum laude from Columbia University and his MD magna cum laude from Harvard Medical School, and completed internship, residency and endocrinology training at the Massachusetts General Hospital. |